Immunic Shares Up 64% on Positive IMU-838 Tests Against Covid-19 >IMUX
6:27 am ET April 22, 2020 (Dow Jones) Print
By Chris Wack
Immunic Inc. shares rose 64% to $14.07 premarket after the company said its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2.
The company said IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with Covid-19.
In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials. These positive results have encouraged Immunic to prepare a clinical development program for IMU-838 as a potential treatment option for patients with Covid-19 and potential other, future viral pandemics.
IMU-838 is already being investigated in ongoing phase 2 clinical trials in patients with relapsing-remitting multiple sclerosis, ulcerative colitis and primary sclerosing cholangitis. IMU-838's antiviral activity has previously been demonstrated in vitro against human immunodeficiency virus, hepatitis C virus, human cytomegalovirus, Arenavirus and Influenza A virus.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 22, 2020 06:27 ET (10:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
New York Yankees and Duke Basketball
